Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths.
BioCardia, Inc. is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Peter A. Altman Ph.D. |
Contact Details
Address: 320 Soquel Way Sunnyvale, California 94085 United States | |
| Phone | 650-226-0123 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U5074 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Altman Ph.D. | Chief Executive Officer, President and Director |
| David McClung | Chief Financial Officer |
| Edward M. Gillis | Senior Vice President of Devices |
| Dr. Sujith Shetty MBBS | Chief Medical Officer and Vice President of Clinical and Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | PRE 14A | Other preliminary proxy statements |